{"organizations": [], "uuid": "687b06af6e91f27fb7bd93d3ff74e538246d4fa6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-neurocrine-biosciences-reports-q4/brief-neurocrine-biosciences-reports-q4-earnings-per-share-0-07-idUSASB0C5HN", "country": "US", "domain_rank": 408, "title": "BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-13T23:09:00.000+02:00", "replies_count": 0, "uuid": "687b06af6e91f27fb7bd93d3ff74e538246d4fa6"}, "author": "", "url": "https://www.reuters.com/article/brief-neurocrine-biosciences-reports-q4/brief-neurocrine-biosciences-reports-q4-earnings-per-share-0-07-idUSASB0C5HN", "ord_in_thread": 0, "title": "BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07", "locations": [], "entities": {"persons": [{"name": "sha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-neurocrine biosciences", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "neurocrine biosciences inc", "sentiment": "none"}, {"name": "neurocrine biosciences", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 13, 2018 / 9:10 PM / in 13 minutes BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07 Reuters Staff 1 Min Read Feb 13 (Reuters) - Neurocrine Biosciences Inc: * NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018 * Q4 EARNINGS PER SHARE $0.07 * Q4 REVENUE $94.5 MILLION * NEUROCRINE BIOSCIENCES- REVENUE MILESTONES UNDER ABBVIE AGREEMENT FOR 2018 EXPECTED TO BE $40 MILLION CONTINGENT ON FDA APPROVAL OF ELAGOLIX FOR ENDOMETRIOSIS * ‍ONGOING OPERATING EXPENSES FOR 2018 SHOULD APPROXIMATE $365 MILLION TO $395 MILLION​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-13T23:09:00.000+02:00", "crawled": "2018-02-13T23:29:36.019+02:00", "highlightTitle": ""}